Rritual Mushrooms Inc.

The QualityStocks Daily Newsletter would like to spotlight Rritual Mushrooms Inc..

Rritual Mushrooms Inc. is a private company founded in 2019, whose declared purpose is to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets.

The company manufactures premium plant-based products such as small-batch elixir powders, and each product features mindfully selected medicinal mushrooms and adaptogenic herbs. Pursuing customers with various need-states, Rritual offers products that fit every lifestyle.

Suite of Premium Rritual(TM) Products

Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.

The initial product line includes:

• Chaga (immune booster) – Full of bioactive polysaccharides, Rritual’s Chaga blend combines the Chaga mushroom with Eleuthero root for optimal immune system benefits.
• Lion’s Mane (brain booster) – Designed to support cognitive function and brain health, Lion’s Mane is paired with Rhodiola root. The elixir can also help the body manage stress.
• Reishi (stress support) – Rich in polysaccharides, triterpenes, amino acids and fatty acids, the Reishi blend is infused with Ashwagandha root. This combination aims to help the body and mind fight anxiety, with long term effects that may improve quality of sleep for those with restless minds.

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Hart said in a news release.

Rritual CEO David Kerbel noted that the company is proud to bring together age-old mushroom consumption practices and data-backed research to create new formulas that meet the needs of modern consumers. “Whether to relieve stress, increase mental output or boost immunity, we want to be a trusted and effective component of a consumer’s daily health and wellness routine,” he added.

Rritual Timeline

According to its investor presentation, Rritual has already fulfilled most of the milestones it set for Q1 and Q2 2020 as part of its growth and development timeline. So far, the company has completed formulation R&D, product line development, test marketing, brand development, logistics partnerships and agreements, initial distributor partnerships, seed financing and the phase one launch of its product suite.

Rritual E-Commerce Rollout Strategy

The company’s strategy for e-commerce rollout success consists of direct-to-consumer (D2C) sales through the use of multiple online platforms and through team connections to facilitate rapid expansion within the market.

In the first stage, Rritual will use its own website and Amazon to facilitate its D2C initiative, followed by leveraging its team connections to sell products through planned specialty e-commerce channels such as Costco, CVS, Walmart, and Vitacost using preexisting relationships.

Brick-and-Mortar Rollout Strategy

Using partnerships already in place with The Jet Collective and leveraging the preexisting connections of its team for direct discussions with global retail brands, Rritual’s brick-and-mortar strategy features a two-stage rollout that targets 15 leading retailers.

In the first stage, Rritual aims to launch with four non-competing chains, while utilizing best practice agreements (320 Sprouts stores, 330 H-E-B stores, 240 Meijer stores and 1,600 Publix stores). In stage 2, distribution is expected to advance to additional retail establishments (100 Wegmans stores, 77 Fresh Thyme stores, 440 Whole Foods stores, 120 Shaw’s stores, 400 Stop & Shop stores, 300 Wakefern/Shoprite stores, 610 Vitamin Shoppe stores, 90 Bartell Drug stores, 40 Giant Eagle market district stores and 1,800 Target stores), while collaboration with Kroger will take place within two sub-markets (300 Ralphs stores and 120 Harris Teeter stores).

Market Growth Outlook

As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth. At this time, no dominant brand is in place, and there remains an absence of a premium brand to lead the category.

The entire functional food market is currently valued at more than $275 billion, with global shifts supporting wellness and a 7.9% CAGR forecast through 2025. Demand for functional mushrooms is also growing, with a forecast rise from $23 billion to $34 billion by 2024 as a result of growing popularity due to the superfood’s unique properties that have been shown to boost immunity, cognitive function and more. The worldwide functional mushroom market is projected to exceed $50 billion by 2025, with recent data indicating an increase in demand for key mushroom varieties of up to 800%.

Management Team

David Kerbel, CPC, is CEO of Rritual and has over 30 years of senior experience in retail, brokerage and CPG industries. From 2008 to 2011, Kerbel served as Senior Vice President of Sales for Celsius Holdings Inc., helping that company achieve a number of important milestones. During his tenure, Celsius grew its retail sales from $400,000 to a multimillion-dollar figure, developed nationwide representation with CROSSMARK Inc. and established distribution with industry giants such as 7-Eleven, Ralph’s, C&S, Costco, BJ’s Wholesale, CVS, Walgreens, Walmart, Rite Aid, Target, Duane Reade and Stop & Shop. In total, Celsius’ new distribution stemming from Kerbel’s direct efforts led to $36 million in incremental sales in 2010 alone. He also implemented new procedures that led to a 10 percent reduction in operating expenses. Kerbel brings tremendous experience to the Rritual team, as well as vital relationships with industry leaders such as Walmart, Costco, Kroger, Walgreens, CVS, 7-Eleven, Safeway, Publix, Sprouts and more.

Warren Spence is the COO and a Director of Rritual. He has over 25 years in the food and beverage industry. His roles within the industry have included senior positions with brands like Red Bull and Olivieri. His specialization is in supply chain and operations systems. He was appointed Head of Supply Chain for Nude Beverages in 2019.

Dr. Mike Hart, MD, is the President of Rritual. His work has been published in peer-review journals about therapies involving cannabis and ketamine. His outspoken stance on these subjects landed him an appearance on the Joe Rogan Experience Podcast in 2019. On-air, he discussed the use of psychedelic medicines as a treatment for mental health conditions, including PTSD.

Stacie Gillespie is CCO and Director of Formulations for Rritual. She has over 25 years of leadership in the branding and product strategies used by wellness companies. She has leveraged this expertise for companies such as Aura Cacia, MegaFood and Gaia Herbs. She is the creator of multiple award-winning consumer health products.

Sarton Molnar-Fenton is Vice President of Sales-USA for Rritual. She started her career with Vitamin Water, with other large companies under her belt, including Danone, as a District Manager. She worked with Nestle on its Tribe Hummus brand and played an integral part in relaunching the brand, gaining category share and establishing product development partnerships with companies like Trader Joe’s. She also played a key role in launching the Hydralyte brand in the United States.

Scott Naccarrato is the company’s Vice President of Sales-Canada. He is experienced in sales with a deep connection in retail. Recently, he worked with Nutiva, assisting in the pioneering of Organic MCT oil, healthy fats and the plant-based protein categories. He is data-oriented in his approach, which has resulted in over $100 million in sales and double-digit year-over-year growth for the brands of which he has been a part.

Investment Considerations

• Rritual’s suite of premium functional mushroom and adaptogenic elixirs is designed to offer various health benefits, such as increased immunity, cognitive function, stress management and more.
• The company’s products are expected to be available online through Rritual’s site and Amazon by fall 2020.
• The Rritual team has extensive ties and influential relationships with leading retail businesses, providing a wide market for growth.
• The functional mushroom industry has no clear and dominant leader, allowing Rritual to target this role with its premium products. Rritual is currently the only premium brand on the market.
• The global functional mushroom market is expected to exceed $50 billion by 2025, putting Rritual in the position for success.
• Functional mushroom demand is expected to rise from $23 billion to $34 billion by 2024.

Recent News

• Rritual Mushrooms Inc. Engages InvestorBrandNetwork
• Rritual Mushrooms Inc. is “One to Watch”
• Rritual, Premium North American Brand in the Emerging Functional Mushroom Market Announces Dr. Mike Hart as President

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth Corp. (NASDAQ: DRIO) was featured today in a publication from BioMedWire, examining how, these days, it is common to see members of a female soccer team training close to the ground that is being used by their male counterparts, and this is pleasing given how far society has come before accepting that females can participate in contact sports. However, lots of sports scientists noticed that females were complaining more about the effects of heading the ball when compared to their male counterparts. It now turns out that there is a scientific reason for that as explored below.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

• AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
• Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Wednesday's trading session at $15.89, up 3.5854%, on 55,713 volume with 616 trades. The average volume for the last 3 months is 265,032 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

• Heading Soccer Balls Causes More Damage to Females than Males
• Laser-Welded Sugar: The New Technique to Repair Damaged Blood Vessels?
• Engineers Link Computers to Brains Using 3D Implants

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how it is a well-known fact that electricity and water do not go well together. Most electronics shouldn’t be put in water and manufacturers constantly caution consumers against using their electronics in or near a wet environment. And for the most part, it’s not that hard to keep your toaster, television, or hairdryer away from water. But what if you are driving an electric vehicle (“EV”) and have to charge in the rain?

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
• Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday's trading session at $7.45, up 0.539811%, on 385,691 volume with 2,789 trades. The average volume for the last 3 months is 1,474,433 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

• Is it Dangerous to Charge Your EV in the Rain?
• Net Element Inc. (NASDAQ: NETE), Mullen Technologies Announce Facility Build-Out, Pre-Sales of Fully Electric EV
• Polaris Inc. (NYSE: PII) and Zero Motorcycles Team Up to Produce Electric Snowmobiles

Processa Pharmaceuticals Inc. (NASDAQ: PCSA)

The QualityStocks Daily Newsletter would like to spotlight Processa Pharmaceuticals Inc. (NASDAQ: PCSA).

Processa Pharmaceuticals (NASDAQ: PCSA) has closed its previously announced underwritten public offering of 4,800,000 shares of common stock, which were offered to the public for $4 per share. The clinical-stage biopharmaceutical company, which focuses on the development of drug products intended to provide treatment for and improve the survival and/or quality of life of patients who have a high unmet medical need condition or who have no alternative treatment, announced that the public offering resulted in gross proceeds of approximately $19.2 million. To view the full press release, visit http://ibn.fm/0thEx

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (FDA) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in their selected indications.

Development Pipeline

The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa:

1. Acquires drugs that already have some clinical data to support the targeted treatment – whether it be the drug itself, an analog of the drug or a drug with similar pharmacological targets;
2. Navigates through the FDA, collaborating with the reviewers to define a complete development program; and
3. Develops each drug over the course of 2-5 years, out-licensing the drug either just prior to pivotal study after Phase 2b or after the completion of the pivotal study.

Processa’s current development pipeline features multiple drug candidates, including PCS499 and PCS100. The company has also announced three additional licensing agreements since June 2020, further bolstering its clinical efforts. Each drug is briefly described below.

PCS6422

On August 27, 2020, Processa announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU) to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to increase the anti-cancer related metabolites.

An IND for a Phase 1B study was cleared by the FDA in May 2020. The study will evaluate the safety and tolerability of several dose combinations of PCS6422 and capecitabine in advanced GI tumor patients. Processa intends to enroll the first patient in 1H2021, obtain interim results, and have a final report completed in 2H2022.

“Having worked on 5-FU and other cancer agents in the past, adding PCS6422 to our pipeline and expanding our involvement in oncology was an easy decision given the significant impact that PCS6422 may have on improving the efficacy and safety of capecitabine or other fluoropyrimidines,” CEO Dr. David Young said of the agreement.

PCS499

PCS499 as a potential treatment for necrobiosis lipoidica (“NL”) was first presented to the FDA in a pre-IND meeting in 2018. In 2019, it was the subject of an IND submission and a promising Phase 2 safety study. On March 30, 2020, Processa announced a successful meeting with the FDA regarding the design and execution of the next clinical study to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

“We are pleased with the outcome of the FDA meeting and the feedback we received from the FDA. We believe that the results from our completed Phase 2 trial in NL patients, especially those with more severe ulcerated forms of NL, are encouraging and we appreciate the guidance provided by the FDA regarding our next clinical trial and the requirements to support our NDA submission,” Dr. David Young, CEO of Processa, stated in the news release.

NL is a chronic, disfiguring condition affecting the skin and tissue under the skin, typically on the lower extremities, with no currently FDA-approved treatments. More severe complications can occur, such as deep tissue infections and osteonecrosis, threatening the life of the limb. Approximately 22,500 – 55,500 people in the United States and more than 150,000 – 400,000 people worldwide are affected by the ulcerated form of NL.

YH12852

On August 20, 2020, Processa announced its entry into an agreement with Yuhan Corporation, a South Korean firm, to license YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders. Under the terms of the agreement, Processa will acquire the rights to a portfolio of patents with an exclusive license to develop, manufacture and commercialize YH12852 globally, excluding South Korea.

YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. The less selective 5-HT4 agonists, such as cisapride, have been removed from the market because of the cardiovascular side effects associated with the drugs binding to other receptors, especially 5-HT receptors other than 5-HT4.

CEO Dr. David Young called the agreement “further evidence of Processa’s commitment to seek out novel treatments for unmet medical conditions.” Processa intends to meet with the FDA in early 2021 to further define the clinical development program. In 2021, Processa expects to initiate a Phase 2 trial in a functional GI motility-related disorder that that needs better therapeutic options, such as postoperative ileus and opioid-induced constipation.

ATT-11T

On June 1, 2020, Processa announced its entry into a licensing agreement with Aposense Ltd. for the patent rights and know-how to develop and commercialize ATT-11T, a next generation irinotecan cancer drug. In the release, CEO Dr. David Young noted that the licensing deal fit with Processa’s strategy to “continue to bring innovative products to patients with an unmet medical need condition.”

ATT-11T is a novel lipophilic anti-cancer pro-drug that is being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule on ATT-11T allows ATT-11T to bind to cell membranes to form an inactive pro-drug depot on the cell, with SN-38 preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic is expected to make the therapeutic window of ATT-11T wider than irinotecan, such that the anti-tumor effect of ATT-11T will occur at a much lower dose than irinotecan with a milder adverse effect profile than irinotecan. The wider therapeutic window will likely lead to more patients responding with less side effects when on ATT-11T compared to irinotecan.

The ATT-11T licensing agreement is conditioned upon Processa’s closing of a satisfactory financing round and the listing of the company’s shares on the Nasdaq or NYSE, among other conditions.

PCS100

On September 3, 2020, Processa announced its entry into an exclusive worldwide license agreement with Akashi Therapeutics to develop and commercialization Akashi’s lead drug, HT-100. Rebranded PCS100, the candidate is an anti-fibrotic, anti-inflammatory drug demonstrated to have some clinical anti-fibrotic effect in children. Processa intends to develop PCS100 first in rare adult fibrotic related diseases such as focal segmental glomerulosclerosis (FSGS), idiopathic pulmonary fibrosis (IPF) or Scleroderma, where there are still few therapeutic options.

Management Team

David Young, Pharm.D., Ph.D. is the CEO and founder of Processa. He has over 30 years of pharmaceutical research, drug development and corporate experience. Young has served in leadership roles with a number of pharmaceutical firms throughout his career, including serving as founder and CEO of Promet Therapeutics LLC since 2015 and as Chief Scientific Officer of Questcor Pharmaceuticals from 2009 to 2014. At Questcor, he was responsible for working with the FDA on modernizing the Acthar Gel label and for obtaining FDA approval in infantile spasms. In total, Young has met with the FDA more than 100 times on more than 50 drug products and has been a key team member on more than 30 NDA/supplemental NDA approvals.

Sian Bigora, Pharm.D., is Processa’s Chief Development Officer and founder. She has over 20 years of pharmaceutical research, regulatory strategy and drug development experience, working closely with Young. Prior to joining Processa, Bigora served as Co-Founder, Director and Chief Development Officer at Promet Therapeutics LLC and as Vice President of Regulatory Affairs at Questcor Pharmaceuticals from 2009 to 2015, where she led efforts to modernize the Acthar Gel label and obtain FDA approval in infantile spasms – events which were of material importance to Questcor’s subsequent success.

Patrick Lin is Chief Business & Strategy Officer and founder of Processa. He has over 20 years of financing and investing experience in the biopharma sector. Prior to joining Processa, Lin served as Co-Founder and Chairman of Promet Therapeutics LLC. He is also founder and managing partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies.

James Stanker has served as CFO of Processa since 2018. He has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal management and strategy. He served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016, where he was responsible for managing audit quality in the Atlantic Coast market territory.

Wendy Guy is the Chief Administrative Officer and founder of Processa. She has more than two decades of experience in business operations, having worked closely with Young over the last 18 years in corporate management and operations, HR and finance. Prior to joining Processa, she was Co-Founder, Director and Chief Administrative Officer of Promet Therapeutics LLC and Senior Manager, Business Operation over the Maryland office for Questcor Pharmaceuticals.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), closed Wednesday's trading session at $4.40, up 7.8405%, on 77,940 volume with 353 trades. The average volume for the last 3 months is 9,133 and the stock's 52-week low/high is $6.00/$18.00.

Recent News

• Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting
• Processa Pharmaceuticals Closes $19.2 Million Public Offering
• Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is "One to Watch"

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, is slated to present at an upcoming LD Micro virtual event. GNPX’s Zoom presentation is scheduled for Wednesday, Oct. 14, at 11 a.m. ET. The presentation will feature Genprex president and CEO Rodney Varner, who will deliver a corporate presentation and then participate in a Q&A. Investors and others interested in viewing the presentation can register at https://ibn.fm/MiDEy. To view the full press release, visit http://ibn.fm/RdBSZ

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprexâ„¢ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprexâ„¢, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprexâ„¢ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprexâ„¢.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $3.71, up 5.3977%, on 495,461 volume with 1,765 trades. The average volume for the last 3 months is 1,296,078 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

• Genprex Inc. (NASDAQ: GNPX) CEO Scheduled to Present at LD Micro Event
• Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate
• Why Healthcare Professionals Should Utilize Social Media

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company focused on unlocking data and insights for publicly traded companies through Sequire, its SaaS platform, announced that it had recently closed the acquisition of LD Micro, a leading data and event company serving the small and micro-cap space (https://nnw.fm/BhE2C). SRAX will pay a total consideration of 1.6 million new Class A SRAX common shares to LD Micro’s shareholders, which will be subject to a 36-month lock-up in addition to four quarterly installments of $1 million, with the first payment made upon the closing of the acquisition.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $2.61, up 0.384615%, on 22,207 volume with 158 trades. The average volume for the last 3 months is 134,420 and the stock's 52-week low/high is $1.04999995/$3.35739994.

Recent News

• SRAX Inc. (NASDAQ: SRAX) Announces Acquisition of Micro-Cap Specialist Data Company, LD Micro
• SRAX Inc. (NASDAQ: SRAX) Appoints Digital Media Exec as BIGtoken CEO
• SRAX Inc. (NASDAQ: SRAX) Announces BIGtoken to Become Separate Public Company

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc. (NASDAQ: SGLB) was featured today in a publication from PennyStocks.com, examining how it doesn’t matter if you’re looking at small cap penny stocks or larger cap ones, if they’re trending, someone’s watching. The name of the game with these cheap stocks is simple: make money quickly. Some choose to map out a strategy for day trading and scalping while others focus on longer-term swing trading or even investing in penny stocks . It’s important to understand that if you’re looking to navigate these volatile waters, a strategy is important.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $2.58, up 15.1786%, on 1,124,589 volume with 3,273 trades. The average volume for the last 3 months is 1,385,533 and the stock's 52-week low/high is $1.95000004/$11.6999998.

Recent News

• What Are The Best Penny Stocks Today? 4 For Your Watch List
• Sigma Labs Inc. (NASDAQ: SGLB) Announces Launch of PrintRite3D(R) Lite IPQA(R), Award of First Contract for New Solution
• Sigma Labs Inc. (NASDAQ: SGLB) Announces Contract, Plans to Begin Production Deployment of PrintRite3D Software

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” To view the full article, visit: https://ibn.fm/N9ZB3

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

• Adjustment Disorder with Anxiety
• Generalized Anxiety Disorder
• Postpartum Anxiety
• Perioperative Anxiety
• Panic Disorder
• PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

• Postpartum Depression
• Treatment-resistant Depression
• Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

• Major Depressive Disorder
• Neuropathic Pain
• Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
• Epilepsy
• Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Wednesday's trading session at $0.7036, up 0.514286%, on 411,607 volume with 1,127 trades. The average volume for the last 3 months is 2,273,209 and the stock's 52-week low/high is $0.294299989/$1.48619997.

Recent News

• Why VistaGen Therapeutics (NASDAQ: VTGN) Is 'One to Watch'
• Fecal Transplants Can Rebalance the Microbiota of Infants Born by C-Section
• VistaGen Therapeutics Inc. (NASDAQ: VTGN) is "One to Watch"

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) was featured today in a publication from MiningNewsWire, examining how there is a universal call to shift away from our reliance on fossil fuels, and the push to switch to cleaner renewable energy has created a huge demand for several minerals, such as copper, manganese and cobalt. At the moment, this demand is being met by terrestrial mines, but the allure of the vast mineral deposits on the planet’s sea beds has brought the possibility of deep-sea mining closer than ever before.

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

• The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
• In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
• The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Wednesday's trading session at $0.1973, up 1.1795%, on 151,616 volume with 37 trades. The average volume for the last 3 months is 330,235 and the stock's 52-week low/high is $0.047449998/$0.27000001.

Recent News

• Deep-Sea Mining: Mouthwatering Prospects, Yet Disturbing Questions Remain Unanswered
• Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) Shares Road Map to Production, Promising Drill Program Results
• How to Implement Formalization of the Artisanal Mining Sector in Africa

180 Life Sciences Corp.

The QualityStocks Daily Newsletter would like to spotlight 180 Life Sciences Corp..

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition company (“SPAC”) that previously entered a definitive agreement to acquire 180 Life Sciences, a clinical-stage biotechnology company, on Tuesday announced continued expansion of 180 Life Sciences’ robust intellectual property (“IP”) portfolio. To view the full press release, visit https://ibn.fm/7zPGg

KBL Merger Corp. IV (NASDAQ: KBLM), a special purpose acquisition corporation (SPAC), announced that, in connection with its previously detailed merger agreement with 180 Life Sciences, it consummated a bridge financing on June 29, 2020, and submitted its latest S4 filing with the SEC on August 28, 2020. It expects to close the business combination in Q4 2020. Following the merger, the company will be listed on the Nasdaq Capital Market under ticker symbol ‘ATNF’.

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.

KBLM has valued 180 Life Sciences at $175 million, with the acquisition being carried out via a share swap through which each share of 180 Life Sciences will be exchanged for one share of KBLM.

Drug Development Programs

180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies.

The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trials with first results expected in 2021. Further clinical trials are scheduled to begin by the end of 2020. The company has two additional programs that are in the preclinical stage and are showing promising results.

• Fibrosis & Anti-TNF (Phase 2b/3 Trials): Based at the Kennedy Institute within Oxford University, the fibrosis and anti-TNF program is being led by Professor Jagdeep Nanchahal, a surgeon-scientist who has been running the phase 2 trials, and Professor Sir Marc Feldmann, a renowned immunologist and one of the pioneers of anti-TNF therapy. The program is designed to address four critical areas of inflammation:
  1. The phase 2b/3 trial evaluating the treatment of early stage Dupuytren’s disease (DD) is a fully grant-funded and enrolled study, with top line data expected to be available by Q4 2021.
  2. The phase 2b trial studying the treatment of frozen shoulder is likewise grant-funded and is scheduled to be initiated by Q3 2021.
  3. The phase 2 trial in post-operative cognitive deficit (POCD) is anticipated to commence in Q4 2021.
  4. Preclinical studies in liver fibrosis and nonalcoholic steatohepatitis (NASH) are set to begin in late 2020.
• Inflammatory Pain (Preclinical): Directed by Professor Raphael Mechoulam at the Hebrew University in Israel, this program is focused on discovering novel compounds to treat chronic inflammatory pain.
• A7nAChR (Preclinical): Led by Professor Lawrence Steinman and Dr. Jonathan Rothbard, 180 Life Sciences is seeking to develop a treatment for ulcerative colitis in ex-smokers by targeting the a7nAChR, a nicotine receptor in the body and a central factor in the body’s method of controlling inflammation.

Market Size for Anti-Inflammatory Medication

According to a study carried out by Allied Market Research, the anti-inflammatory therapeutics market is expected to grow to an approximate $106.1 billion annual market size in 2020, registering a CAGR of 5.9% during the period from 2015 to 2020.

Ranging from asthma treatments to targeting the causes of diseases such as arthritis, multiple sclerosis, psoriasis and inflammatory bowel disease, anti-inflammatory therapeutics have seen a sharp increase in usage, particularly given that they allow for medical responses that are more targeted and effective while possessing lesser side effects relative to conventional drugs.

Management Team

Professor Sir Marc Feldmann, Co-Chairman, is known to be a pioneer of anti-TNF therapy, which seeks to suppress the immune system by blocking the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. As of today, anti-TNF therapy drugs have become the world’s largest drug class, with sales estimated at over $40 billion per annum. Feldmann has received seven international awards for biomedical innovation over the years, including the Crawford and Lasker awards, and he is a member of the Royal Society.

Professor Lawrence Steinman, Co-Chairman, is a scientific luminary, having discovered the role of integrins, which led to the creation of Natalizumab, a highlight effective treatment for multiple sclerosis and inflammatory bowel disease. Steinman is a member of the National Academy of Sciences and has received four international awards for biomedical innovation, including the Charcot Prize. Prior to joining 180 Life Sciences, Steinman founded Centocor, a pharmaceutical company that was sold to Johnson & Johnson for $4.9 billion.

Dr. James N. Woody, CEO, was instrumental in the discovery of Remicade as Chief Scientific Officer at Centocor. Previously, Woody founded Avidia and Proteolix, both of which were subsequently sold to Amgen, and he was a General Partner at Latterell Venture Partners. Boasting over 25 years of pharmaceutical research and management experience, Woody was also previously the general manager of Roche Biosciences, the former Syntex Pharmaceutical Company.

Investment Considerations

• 180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value.
• The company has a large and expanding patent portfolio.
• The risks associated with the company’s drug development efforts are mitigated through the concurrent advancement of multiple programs in different stages of development.
• 180 Life Sciences decreases costs and expedites time to market through the use of grant funding, cost-effective international trials and recruitment of hospital-based luminaries who attract teams of excellence.

Recent News

• 180 Life Sciences Corp. Continues to Broaden Global IP Portfolio, Expand Internal Pipeline
• 180 Life Sciences Corp. Setting the Stage for Success in Bringing Novel Products to Market
• 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

Mobius Interactive Ltd.

The QualityStocks Daily Newsletter would like to spotlight Mobius Interactive Ltd..

Mobius Interactive, a new online gaming operator with a variety of diverse offerings, recently entered a new partnership with AffPapa, a unique platform that allows operators and affiliates to find each other. An article discussing this notes the “well-timed collaboration” designed to ease the process of finding partners and overcome challenges. “By joining our affiliate site with the AffPapa global affiliate and operator partnership platform, MobiusAffiliates.com will be a valuable addition to its affiliate directory, allowing space for significant exposure and growth over its critical launch period,” stated Mobius CEO Lynn Pearce. To view the full article, visit https://ibn.fm/LVemd

Mobius Interactive Ltd. is an online gaming operator launching in September 2020 with a variety of unique offerings catering to diverse demographic groups. In partnership with Ultra Play, a leading eSports and iGaming platform, Mobius Interactive is seeking to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance customer engagement by leveraging state-of-the-art customer relationship management systems and joint-ventures with over 600 VIP and Master gaming affiliates.

Array of Brands

Mobius Interactive is seeking to target a variety of customer segments and geographies through its diverse brand offerings, including:

• Aragon Casino: Austria, Finland, the Balkans, Canada, Africa and New Zealand
  Catering to consumers aged 21 to 45, Aragon Casino brands itself along the lines of medieval fantasy, mimicking elements from the likes of The Walking Dead and Game of Thrones.
• Club Double: Austria, India, Brazil, Finland, Canada, Africa and New Zealand
  Targeting the 30 to 65 age demographic, Club Double is designed to exude a classic yet magical old Hollywood and vintage Miami & Las Vegas air.
• MobiusBet: Germany, Austria, Switzerland, Brazil, Latin America, New Zealand and India
  MobiusBet is designed to appeal to the 18- to 38-year-old eSports community, bringing together loyalty programs, targeted gamification and product merchandising in one seamless package.

Key Differentiating Indicators

Mobius Interactive has designed its platform with a number of key differentiation traits relative to its target market. These include:

• The use of affiliates: Mobius Interactive has partnered with over 600 VIP and Master gaming affiliates, who will introduce high-value players to the company’s award-winning iGaming platform. Mobius added over 150 proven affiliates in Europe, Brazil, Finland and New Zealand over a period of just 20 days.
• eSports Focus: Mobius.Bet, Mobius Interactive’s dedicated eSports hub, will cater to the quickly growing eSports segment, which is expected to rise to a value of $1.7 billion in 2021. With Mobius’ COO being one of the original founders of the eSports.com brand, the company aims to capitalize on this growing segment of the gaming industry.
• Customer Relationship Management (CRM): Mobius has partnered with Solitics, a new and real-time CRM system, enabling the company to personalize customers’ gaming experiences in an interactive and highly intelligent manner.
• Loyalty & Gamification: Mobius Interactive is set to introduce a unique loyalty and gamification program designed to increase customer engagement from signup. Loyalty and gamification programs have been proven to increase daily active wagering volumes by 30% while simultaneously increasing daily player activity by 60%. Furthermore, the introduction of these programs can help lower the company’s customer acquisition costs while adding a differentiating element to its platform.

Partnership with Puurl

Puurl provides a solution that embeds eGaming platforms into any existing online e-commerce store. First, shoppers can install the Puurl add-on to their browsers. Then, when visiting their preferred e-commerce stores, players will be prompted to bet, with the potential to win the products they’re browsing. The Puurl solution enables e-commerce operators and eGaming platforms to earn additional gambling revenues – even when their players are shopping. Through its partnership with Puurl, Mobius Interactive will look to add a unique revenue stream to complement its core business operations.

Management Team

Lynn Pearce, CEO, is an experienced, data-driven, commercially focused, strategic brand marketer with over 15 years of proven success in the global gaming industry, from land-based casinos in the UK to online gaming companies offering sports betting, poker and casino games. She was head-hunted to join a startup in Prague that launched 26 casinos, becoming profitable within the first three months of operation, before she relocated to Malta to join a leading B2B casino software development company as head of marketing, where she led global marketing, PR, product development, branding and go-to-market campaigns, retaining full control of a six-month budget of €1 million to increase brand awareness and customer engagement. She recently returned to the B2C side of gaming to launch three new brands in Germany, Brazil and India. She writes articles regularly for Infinity Gaming Magazine and has been a judge for the prestigious International Gaming Awards, a significant event for the gaming industry held each year prior to the largest gaming exhibition of the year, ICE London.

Robin Lawson, Vice President & COO, has been involved in iGaming for over 10 years, successfully founding two VIP casino departments across international locations in Latin America, as well as startup company Tabella in Europe. He most recently co-founded and acted as COO for eSports.com, which raised over $5.5 million as a startup ICO and was sold to German media giant ProSieben. Lawson is also a senior iGaming consultant for startup casino groups and an advisor to blockchain-based tech groups. His long-time experience and proven track record in startup organizations demonstrate his operational leadership skills.

Nicholas de Freitas, Vice President, Marketing, is one of the pioneers of digital stills photography for major retail companies in Africa and Australia. He left to start up UrbanActive, an outsourcing agency, working as marketing project manager and implementing major retail projects. He received his certification in digital marketing from the University of Stellenbosch. He has worked over the past few years as the marketing manager for various poker rooms and casinos, liaising and building relationships with software developers, successfully implementing a number of casino and poker products and holding regular weekly report sessions with the heads of all divisions of the company, spanning South Africa, Canada, Malta, Norway and Costa Rica.

Gary Eldridge, Chairman, is an experienced entrepreneur with a history of working in the venture capital and private equity industry. He is skilled in capital markets, M&A and funding startups and is a strong business development professional. For the past 30 years, he has created and managed numerous public and private companies in Canada, the U.S., Amsterdam, London, Zurich, Dusseldorf, Singapore and Panama. In addition to holding the role of chairman of the company, Eldridge is acting as a mentor to the team, assisting with the financials and structure of the company while allowing the team to be fully focused on Mobius’ growth and operations.

Recent News

• Mobius Interactive Ltd. Enters ‘Well-Timed Collaboration’ with AffPapa
• Mobius Interactive Ltd., UltraPlay to Enhance Customer Engagement Through Loyalty, Gamification Programs and Cutting-Edge Tech
• Mobius Interactive Ltd., AffPapa Announce Collaboration to Facilitate Process of Finding Partners, Overcome Challenges

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

With its slogan proclaiming “the Future of Genetics,” Canadian cannabis company Pac Roots Cannabis (CSE: PACR) clearly places a top priority on producing premium-quality cannabis strains and products. In fact, while some companies may strive to be the largest cannabis grower, Pac Roots Cannabis Corp. maintains that the quality of the product is paramount. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Back in June, the governor of Colorado signed into law a marijuana bill that would promote social equity in Colorado’s marijuana market. On top of that, the bill would give Gov. Jared Polis the power to unilaterally issue pardons for prior marijuana convictions. Decades after the War on Drugs began, it is crystal clear that it has led to the over-policing of certain communities, and the bill was designed to fix some of these wrongs.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

• Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
• Continued stress testing for indoor, high yield, THC and medicinal genetics
• Continued stress testing for outdoor, high yield, THC and medicinal genetics
• Exotic, genetic cloning for the luxury, high margin, cannabis flower market
• Psychoactive/medicinal ratio testing for effect and
• Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

• Global testing in different microclimates to assess genetic and complete systems for optimal yields
• Data collection, testing and optimization to prove process for commercial implementation and
• High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Wednesday's trading session at $0.20, even for the day. The average volume for the last 3 months is 18,956 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

• Pac Roots Cannabis Corp. (CSE: PACR) Committed to Superior Genetics, Quality of Product
• 420 with CNW - Colorado Governor Signs Executive Order Pardoning Thousands of Marijuana Convictions
• 420 with CNW - Environmental Protection Groups Endorse Montana Cannabis Legalization Initiative

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands Innovations Group (OTCQB: KAVL), which focuses on growing and incubating innovative and profitable products into mature, dominant brands, is the sole distributor of the Bidi(TM) Stick, an innovative completely-contained disposable nicotine vaping device designed to provide adult smokers with a premium vaping experience. 

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Wednesday's trading session at $0.51, off by 12.069%, on 91,110 volume with 48 trades. The average volume for the last 3 months is 180,532 and the stock's 52-week low/high is $0.006/$1.09000003.

Recent News

• Kaival Brands Innovations Group Inc. (KAVL) Benefits from Vaping Industry's Explosive Growth
• Kaival Brands Innovations Group Inc. (KAVL) Engages IBN to Maximize Communication, Refine Messaging and Outreach
• Company with Expertise in Smoking Cessation Announces Patent, Creation of Lab

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, was featured in a recent industry report published by investment banking and business development firm Transformation Capital (https://nnw.fm/XhXSO); the report listed SHRG as one of the fastest-growing small-cap companies in the space.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Wednesday's trading session at $0.234375, off by 2.3438%, on 81,947 volume with 19 trades. The average volume for the last 3 months is 383,922 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

• Industry Report Features Sharing Services Global Corp. (SHRG) as Top Performer Among Direct Selling Stocks
• Sharing Services Global Corporation (SHRG) Announces Elevate MAX(TM) +, Offering MAX Benefits Plus Extra 'Magic'
• Sharing Services Global Corporation (SHRG) Appoints Two New Directors with Deep Executive Management, International Experience